Upgrade to SI Premium - Free Trial

Pfizer (PFE)

27.72 -0.22 (0.79%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (4/30/24)
- M&A (N/A)
- M&A (N/A)
- M&A (6/30/20 *Est)
- M&A (3/31/23 *Est)
- M&A (12/31/23 *Est)

Latest Headlines

Form 4 PFIZER INC For: Mar 15 Filed by: DAMICO JENNIFER B. March 18, 2024 6:40 PM - SEC Filing Form 4 PFIZER INC For: Mar 15 Filed by: BOURLA ALBERT March 18, 2024 6:40 PM - SEC Filing Pfizer (PFE) to trim its Haleon stake to 24% March 18, 2024 5:24 AM - StreetInsider Pfizer to cut stake in Sensodyne toothpaste-maker Haleon to 24% March 18, 2024 3:09 AM - StreetInsider Form ARS PFIZER INC For: Dec 31 March 14, 2024 9:13 AM - SEC Filing Pfizer (PFE) CEO Albert Bourla's 2023 Total Compensation $21.6M, Down from $33M In 2022 March 14, 2024 9:08 AM - StreetInsider Form DEFA14A PFIZER INC March 14, 2024 9:08 AM - SEC Filing Form DEF 14A PFIZER INC For: Apr 25 March 14, 2024 9:05 AM - SEC Filing Popular stocks with increasing volume: PLTR PYPL SQ FCX INTC BA SOUN COIN BABA PFE March 14, 2024 4:34 AM - StreetInsider European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease March 13, 2024 4:00 AM - BizWire Pfizer (PFE) Reports Positive Overall Survival in Phase 3 Trial of ADCETRIS Regimen March 12, 2024 6:46 AM - StreetInsider Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL) March 12, 2024 6:45 AM - BizWire ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals March 6, 2024 12:05 PM - BizWire Form 4 PFIZER INC For: Mar 04 Filed by: BOURLA ALBERT March 5, 2024 3:56 PM - SEC Filing Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference March 5, 2024 10:00 AM - BizWire ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities March 5, 2024 8:48 AM - BizWire ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses March 4, 2024 1:50 PM - BizWire Form 4 PFIZER INC For: Feb 28 Filed by: BOSHOFF CHRISTOFFEL March 1, 2024 1:29 PM - SEC Filing Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth February 29, 2024 5:40 PM - BizWire Pfizer (PFE) Reports Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO February 29, 2024 8:01 AM - StreetInsider Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults February 29, 2024 8:00 AM - BizWire Form 4 PFIZER INC For: Feb 28 Filed by: Dolsten Mikael February 29, 2024 6:54 AM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: SAHNI PAYAL February 28, 2024 5:26 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: de Germay Alexandre February 28, 2024 5:25 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: Denton David M February 28, 2024 5:18 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: MALIK AAMIR February 28, 2024 5:18 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: JOHNSON RADY A February 28, 2024 5:18 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: LANKLER DOUGLAS M February 28, 2024 5:18 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: McDermott Michael February 28, 2024 5:18 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: Fonseca Lidia February 28, 2024 5:11 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: SUSMAN SALLY February 28, 2024 5:11 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: BOSHOFF CHRISTOFFEL February 28, 2024 5:11 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: BOURLA ALBERT February 28, 2024 5:11 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: Dolsten Mikael February 28, 2024 5:11 PM - SEC Filing Form 4 PFIZER INC For: Feb 27 Filed by: DAMICO JENNIFER B. February 28, 2024 5:11 PM - SEC Filing ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV February 28, 2024 10:04 AM - BizWire Form 4 PFIZER INC For: Feb 23 Filed by: McDermott Michael February 27, 2024 1:48 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: SUSMAN SALLY February 27, 2024 1:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: SAHNI PAYAL February 27, 2024 1:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: BOURLA ALBERT February 27, 2024 1:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: Dolsten Mikael February 27, 2024 1:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: JOHNSON RADY A February 27, 2024 1:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: DAMICO JENNIFER B. February 27, 2024 1:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: LANKLER DOUGLAS M February 27, 2024 1:47 PM - SEC Filing Form 4 PFIZER INC For: Feb 23 Filed by: BOSHOFF CHRISTOFFEL February 27, 2024 1:44 PM - SEC Filing Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference February 26, 2024 10:00 AM - BizWire Pfizer (PFE) Files Mixed Shelf February 23, 2024 4:40 PM - StreetInsider Form S-3ASR PFIZER INC February 23, 2024 4:38 PM - SEC Filing Form S-8 PFIZER INC February 23, 2024 4:38 PM - SEC Filing Popular stocks with increasing volume: PFE RIVN SMCI SQ CVNA WBD PANW MARA ARM February 23, 2024 2:08 PM - StreetInsider Pfizer (PFE) stock is a new Buy at Guggenheim February 23, 2024 5:41 AM - StreetInsider Guggenheim Starts Pfizer (PFE) at Buy, 'Successful Execution Can Drive Upside' February 22, 2024 4:10 PM - StreetInsider Form 10-K PFIZER INC For: Dec 31 February 22, 2024 1:19 PM - SEC Filing Pfizer (PFE) Announces EU Approval of VELSIPITY February 21, 2024 10:36 PM - StreetInsider Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis February 21, 2024 7:48 PM - PR NewsWire Comprehensive study links COVID vaccines to rare but notable adverse effects February 20, 2024 2:36 PM - StreetInsider European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis February 19, 2024 7:45 AM - BizWire Form 4 PFIZER INC For: Feb 14 Filed by: BOURLA ALBERT February 16, 2024 12:55 PM - SEC Filing Form 4 PFIZER INC For: Feb 14 Filed by: DAMICO JENNIFER B. February 16, 2024 12:53 PM - SEC Filing Form 4 PFIZER INC For: Feb 14 Filed by: JOHNSON RADY A February 16, 2024 12:52 PM - SEC Filing Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day February 15, 2024 10:00 AM - BizWire Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032 February 15, 2024 8:45 AM - StreetInsider Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies February 14, 2024 8:30 AM - StreetInsider Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer February 14, 2024 8:00 AM - StreetInsider Form SC 13G/A PFIZER INC Filed by: VANGUARD GROUP INC February 13, 2024 6:00 PM - SEC Filing ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine) February 6, 2024 6:47 PM - BizWire Arvinas (ARVN) and Pfizer (PFE) Announce Vepdegestrant Granted FDA Fast Track Designation February 6, 2024 6:46 AM - StreetInsider Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer February 6, 2024 6:45 AM - StreetInsider ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine) February 5, 2024 11:00 AM - BizWire Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities February 5, 2024 10:00 AM - BizWire Pfizer (PFE) PT Lowered to $28 at UBS January 31, 2024 10:16 AM - StreetInsider Pfizer (PFE) PT Lowered to $32 at DZ Bank January 31, 2024 3:43 AM - StreetInsider Form 8-K PFIZER INC For: Jan 30 January 30, 2024 8:04 AM - SEC Filing Midday movers: GM advances, Apple declines, and more January 30, 2024 7:58 AM - StreetInsider Pfizer fourth-quarter loss shallower than anticipated January 30, 2024 6:57 AM - StreetInsider Pfizer posts surprise 4th quarter profit, but key products miss on sales January 30, 2024 6:51 AM - StreetInsider Pfizer (PFE) Tops Q4 EPS by 28c, Tops on Revenue; Offers Guidance January 30, 2024 6:46 AM - StreetInsider Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance January 30, 2024 6:45 AM - BizWire Form SC 13G/A PFIZER INC Filed by: STATE STREET CORP January 29, 2024 1:05 PM - SEC Filing Pfizer (PFE) February weekly option implied volatility elevated into quarter results January 29, 2024 10:48 AM - StreetInsider Pfizer (PFE): FDA Revises Letter of Authorization for the Emergency Use Authorization for Paxlovid January 29, 2024 9:53 AM - StreetInsider Dow Jones, Nasdaq, S&P 500 weekly preview: FOMC, NFP, Apple, Microsoft and more January 29, 2024 9:16 AM - StreetInsider Pfizer (PFE) February weekly 27.50 straddle priced into quarter results January 29, 2024 4:09 AM - StreetInsider Pfizer (PFE) Announces EMA Validates Type II Variation Application for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer January 26, 2024 12:01 PM - StreetInsider European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer January 26, 2024 12:00 PM - PR NewsWire European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer January 26, 2024 12:00 PM - BizWire Form SC 13G/A PFIZER INC Filed by: BlackRock Inc. January 26, 2024 11:53 AM - SEC Filing Pfizer (PFE) PT Raised to $29 at UBS January 17, 2024 10:06 AM - StreetInsider Form 4 PFIZER INC For: Jan 11 Filed by: JOHNSON RADY A January 12, 2024 4:17 PM - SEC Filing Form 4 PFIZER INC For: Jan 11 Filed by: DAMICO JENNIFER B. January 12, 2024 4:17 PM - SEC Filing Form 4 PFIZER INC For: Jan 11 Filed by: BOURLA ALBERT January 12, 2024 4:16 PM - SEC Filing This stock is a new preferred major pharma pick at Citi January 11, 2024 5:51 PM - StreetInsider Form 8-K PFIZER INC For: Jan 10 January 10, 2024 4:39 PM - SEC Filing Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation January 10, 2024 4:30 PM - BizWire Pfizer (PFE) and Genmab (GMAB) Reports TIVDAK sBLA Accepted for Priority Review by FDA January 9, 2024 6:45 AM - StreetInsider TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer January 9, 2024 6:45 AM - BizWire TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer January 9, 2024 6:45 AM - StreetInsider Pfizer (PFE) Announces EU Approval of TALZENNA with XTANDI for Adult Patients with Metastatic Castration-Resistant Prostate Cancer January 8, 2024 10:58 AM - StreetInsider European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer January 8, 2024 10:35 AM - BizWire Pfizer (PFE) and Illumina (ILMN) downgraded but Merck (MRK) can deliver, declares TD Cowen January 4, 2024 2:30 PM - StreetInsider Popular stocks with increasing volume: JPM SOFI C BABA MSFT PYPL COIN AMC PLTR GOOGL PBR AAL PFE January 4, 2024 10:46 AM - StreetInsider TD Cowen Downgrades Pfizer (PFE) to Market Perform January 4, 2024 5:29 AM - StreetInsider Popular stocks with increasing volume: PFE CSCO COIN C PLTR RIVN SOFI BAC INTC T January 3, 2024 9:46 AM - StreetInsider Popular stocks with increasing volume: PFE C NIO BABA PLTR COIN RIVN T SOFI BAC INTC UBER January 3, 2024 4:04 AM - StreetInsider Form 4 PFIZER INC For: Dec 29 Filed by: Quincey James January 2, 2024 5:50 PM - SEC Filing Form 4 PFIZER INC For: Dec 29 Filed by: NARAYEN SHANTANU January 2, 2024 5:50 PM - SEC Filing Form 4 PFIZER INC For: Dec 29 Filed by: SMITH JAMES C January 2, 2024 5:50 PM - SEC Filing Form 4 PFIZER INC For: Dec 29 Filed by: Echevarria Joseph January 2, 2024 5:50 PM - SEC Filing Form 4 PFIZER INC For: Dec 29 Filed by: JOHNSON RADY A January 2, 2024 5:42 PM - SEC Filing Form 4 PFIZER INC For: Dec 29 Filed by: DAMICO JENNIFER B. January 2, 2024 5:42 PM - SEC Filing Form 4 PFIZER INC For: Dec 29 Filed by: BOURLA ALBERT January 2, 2024 5:42 PM - SEC Filing Pfizer (PFE) option implied volatility bid as share price up 3% January 2, 2024 10:25 AM - StreetInsider Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference January 2, 2024 10:00 AM - BizWire Form 4 PFIZER INC For: Dec 29 Filed by: BOSHOFF CHRISTOFFEL December 29, 2023 6:05 PM - SEC Filing Pfizer (PFE), Sanofi (SNY) and Takeda (TAK) to raise prices on over 500 drugs in the US in January - Reuters December 29, 2023 9:16 AM - StreetInsider Healthcare a contrarian idea into 2024 - these stocks could see upside December 26, 2023 9:42 AM - StreetInsider Form 3 PFIZER INC For: Dec 15 Filed by: de Germay Alexandre December 21, 2023 4:21 PM - SEC Filing Full Article List